<article>
    <h2>A $20 drug in Europe requires a prescription and $800 in the U.S.</h2>
    <div>
<div>
<p>The STAT News article from October 31, 2025, investigates the significant price disparity between Miebo, a medication for dry eye disease, in the United States and Europe. Specifically, it highlights that Miebo costs 40 times more in the U.S. compared to its European counterpart. The article delves into the reasons behind this dramatic price difference, exploring factors such as differing regulatory landscapes, patent protections, market dynamics, and pricing strategies employed by pharmaceutical companies. It examines how the U.S. system allows manufacturers to set prices with fewer constraints compared to the more regulated European markets, where governments often negotiate drug prices to control healthcare costs.</p>

<p>The piece also likely considers the role of insurance companies and pharmacy benefit managers (PBMs) in the U.S., and how their negotiations with pharmaceutical companies influence the final cost to consumers. It probes whether the higher price in the U.S. is justified by factors such as research and development costs, or if it is primarily driven by profit motives. The article may also explore the impact of this price difference on patients, discussing issues like access to medication, financial burden, and potential health disparities. Furthermore, the article likely addresses the broader implications of such pricing discrepancies for the global pharmaceutical market and the ongoing debate about drug pricing reforms.</p>

<h3>Key Points:</h3>
<ul>
<li>Miebo costs 40 times more in the U.S. than in Europe.</li>
<li>The article examines the reasons for this extreme price difference.</li>
<li>U.S. regulations allow for higher drug prices compared to Europe.</li>
<li>European governments negotiate drug prices, keeping costs down.</li>
<li>Insurance companies and PBMs play a role in U.S. drug pricing.</li>
<li>The article explores whether the high price is justified by R&D.</li>
<li>The price difference impacts patient access and financial burden.</li>
<li>The article addresses broader implications for global drug pricing.</li>
</ul>
</div>
</div>
</article>
